RecruitingNCT06195150
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
Sponsor
IRCCS San Raffaele
Enrollment
3 participants
Start Date
Nov 8, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Plain Language Summary
Simplified for easier understanding
This study looks at how kidney tumors in people with Von Hippel-Lindau (VHL) syndrome differ from one another — both within a single tumor and between different tumors in the same person. VHL is a rare inherited condition that causes tumors to grow in the kidneys and other organs.
**You may be eligible if...**
- You have been diagnosed with VHL syndrome
- You have at least 3 kidney tumors larger than 3 cm that need to be surgically removed
**You may NOT be eligible if...**
- You do not have VHL syndrome
- You have fewer than 3 kidney tumors
- You are not scheduled for kidney surgery
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBlood collection
15ml of blood are harvested before surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06195150
Related Trials
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT0722741588 locations
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
NCT070234321 location
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT073002418 locations
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT068633114 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720410 locations